| 摘要 |
PROBLEM TO BE SOLVED: To obtain the subject therapeutic agent useful for treatment of chronic rheumatism by adding a material for inhibiting or neutralizing specific interleukin activities, or a material for inhibiting signal transduction of osteoclastogenesis of the above interleukin. SOLUTION: This therapeutic agent for chronic rheumatism contains (A) a material for inhibiting or neutralizing the activities of interleukin-17, preferably interleukin-17 neutralizing antibody, and/or (B) a material for inhibiting signal transduction of osteoclastogenesis of the interleukin-17, preferably osteoclastogenesis inhibitory factor(OCIF) as an active ingredient. The dosage of the therapeutic agent is preferably carried out by once or twice administrations of 0.05-500 mg dose per 30 days. Preferably, the dosage of the OCIF is carried out by one to several times administration of 0.01-100 mg dose, and in the case of a sustained release preparation, the dosage is carried out by once or twice administrations per seven to 15 days.
|
